Advertisement

ACE-Hemmer und Angiotensinrezeptorantagonisten

  • Manfred Anlauf

Zusammenfassung

ACE-Hemmer und Angiotensinrezeptorantagonisten gehören zu den besonders erfolgreichen Arzneimitteln zur Behandlung kardiovaskulärer und renaler Krankheiten.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Anlauf M (2003): Sartane für alle Hypertoniker? In: Arzneimittelkommission der Deutschen Ärzteschaft: Arzneiverordnungen in der Praxis. 4/2002–1/2003.Google Scholar
  2. Arzneimittelkommission der Deutschen Ärzteschaft (2002): Evidenzbasierte Therapieleitlinien. Empfehlungen zur Therapie der chronischen Herzinsuffizienz. Deutscher Ärzteverlag KölnGoogle Scholar
  3. Berl T, Hunsicker LG, Lewis JB, Pfeffer MA, Porush JG, Rouleau JL et al and the Irbesartan Diabetic Nephropathy Trial Collaborative Study Group (2003): Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy. Ann Intern Med 138: 542–549.PubMedGoogle Scholar
  4. Brenner BM, Cooper ME, De Zeeuw D, Keane WF, Mitch WE, Parving HH et al (2001): Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345: 861–869.PubMedCrossRefGoogle Scholar
  5. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr et al and the National High Blood Pressure Education Program Coordinating Committee (2003): The seventh report on the joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. JAMA 289: 2560–2572.PubMedCrossRefGoogle Scholar
  6. Cohn JN, Tognoni G for the Valsartan Heart Failure Trial Investigators (2001): A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 345: 1667–1675.PubMedCrossRefGoogle Scholar
  7. CONSENSUS Trial Study Group (1987): Effects of enalapril on mortality in severe congestive heart failure: Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 316: 1429–1435.CrossRefGoogle Scholar
  8. Dahlöf B, Devereux RB, Julius S, Kjeldsen SE, Beevers G, de Faire U et al (1998): Characteristics of 9194 patients with left ventricular hypertrophy: the LIFE study. Losartan Intervention For Endpoint Reduction in Hypertension. Hypertension 32: 989–997.Google Scholar
  9. Dahlöf B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, Faire U et al for The LIFE Study Group (2002): Cardiovascular morbidity and mortality in the losartan intervention for endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 359: 995–1003.PubMedCrossRefGoogle Scholar
  10. Dickstein K, Kjekshus J, and the OPTIMAAL Steering Committee, for the OPTIMAAL Study Group (2002): Effects of losartan and Captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Lancet 360: 752–760.PubMedCrossRefGoogle Scholar
  11. Fiather MD, Yusuf S, Kober L, Pfeffer M et al (2000): Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. Lancet 355: 1575–1581.CrossRefGoogle Scholar
  12. Granger CB, McMurray JJV, Yusuf S, Held P et al (2003): Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet 362: 772–776.PubMedCrossRefGoogle Scholar
  13. Hall AS, Murray GD, Ball SG (AIREX Study Group Investigators) (1997): Follow-up study of patients randomly allocated ramipril or placebo for heart failure after myocardial infarction: AIRE extension (AIREX) study. Lancet 349: 1493–1497.PubMedCrossRefGoogle Scholar
  14. Hansson L, Lindholm LH, Niskanen L, Lanke J, Hedner T, Niklason A, Luomanmaki K, Dahlof B, de Faire U, Moriin C, Karlberg BE, Wester PO, Bjorck JE (1999): Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 353: 611–616.PubMedCrossRefGoogle Scholar
  15. Holzgreve H, Nakov R, Beck K, Janka HU (2003): Antihypertensive therapy with verapamil SR plus trandolapril versus atenolol plus chlorthalidone on glycemic control. Am J Hypertens 16: 381–386.PubMedCrossRefGoogle Scholar
  16. ISIS-4 Collaborative Group (1995): ISIS-4: a randomised factorial trial assessing early oral Captopril, oral mononitrate and intravenous magnesium sulphate in 58050 patients with suspected acute myocardial infarction. Lancet 345: 669–685.CrossRefGoogle Scholar
  17. Jafar TH, Stark PC, Schmid CH, Landa M (2003): Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition. A patient-level meta-analysis. Ann Intern Med 139: 244–252.PubMedGoogle Scholar
  18. Kasiske BL, Kalili RSN, Ma JZ, Liao M, Keane WF (1993): Effect of antihypertensive therapy on the kidney in patients with diabetes: a meta-regression analysis. Ann Intern Med 118: 129–138.PubMedGoogle Scholar
  19. Kjeldsen SE, Dahlöf B, Devereux RB, Julius S, Aarup P, Edelman J et al (2002): Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy. JAMA 288: 1491–1498.PubMedCrossRefGoogle Scholar
  20. Laverman GD, Navis G, Henning RH, de Jong D, de Zeeuw D (2002): Dual renin-angiotensin system blockade at optimal doses for proteinuria. Kidney Int 62: 1020–1025.PubMedCrossRefGoogle Scholar
  21. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD for the Collaborative Study Group (1993): The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 329: 1456–1462.PubMedCrossRefGoogle Scholar
  22. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Leiws JB et al (2001): Renopro-tective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345: 851–860.PubMedCrossRefGoogle Scholar
  23. Lindholm LH, Ibsen H, Dahlöf B, Devereux RB, Beevers G, de Faire U et al for The LIFE Study Group (2002): Cardiovascular morbidity and mortality in patients with diabetes in the losartan intervention for endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 359: 1004–1010.PubMedCrossRefGoogle Scholar
  24. Lindholm LH, Dahlöf B, Edelman JM, Ibsen H et al LIFE study group (2003): Effect of losartan on sudden cardiac death in people with diabetes: data from the LIFE study. Lancet 362: 619–620PubMedCrossRefGoogle Scholar
  25. Lithell H, Hansson L, Skoog I, Elmfeldt D, Hofman A, Olofsson B et al for the SCOPE Study Group (2003): The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens 21: 875–886.PubMedCrossRefGoogle Scholar
  26. Mann JF, Gerstein HC, Pogue J, Bosch J, Yusuf S (2001): Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Ann Intern Med 134: 629–636.PubMedGoogle Scholar
  27. Maschio G, Albert D, Ganin G, Locatelli F, Mann JFE et al (1996): Effect of the angio-tensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. N Engl J Med 334: 939–945.PubMedCrossRefGoogle Scholar
  28. Marre M, Lievre M, Chatellier G, Mann JFE et al (2004): Effects of low dose ramipril on cardiovascular and renal outcomes in patients with type 2 diabetes and raised excretion of urinary albumin: randomised, double blind, placebo controlled trial (the DIABHYCAR study). BMJ, doi:10.1136/bmj.37970.629537.0DGoogle Scholar
  29. McMurray JJV, Östergren J, Swedberg K, Granger CB et al (2003): Effects of candes-artan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet 362: 767–771PubMedCrossRefGoogle Scholar
  30. Morgensen CE, Neldam S, Tikkanen I, Oren S, Viskoper R, Watts RW, Cooper ME (2000): Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the Candesartan And Lisinopril Microalbuminuria (CALM) Study. Brit Med J 321: 1440–1444.CrossRefGoogle Scholar
  31. Nakao N, Yoshimura A, Morita H, Takada M, Kayano T, Ideura T (2003): Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial. Lancet 361: 117–124.PubMedCrossRefGoogle Scholar
  32. Neal B, MacMahon S, Chapman N for the Blood Pressure Lowering Treatment Tria-lists’ Collaboration (2000): Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Lancet 356: 1955–1964.PubMedCrossRefGoogle Scholar
  33. Parving H-H, Lehnert H, Bröchner-Mortensen J, Gomis R (2001): The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 345: 870–878.PubMedCrossRefGoogle Scholar
  34. Pfeffer MA, McMurray JJV, Velazquez EJ, Rouleau J-L et al for the Valsartan in Acute Myocardial Infarction Trial Investigators (2003a): Valsartan, Captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 349: 1893–1906.PubMedCrossRefGoogle Scholar
  35. Pfeffer MA, Swedberg K, Granger CB, Held P et al (2003b): Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 362: 559–766Google Scholar
  36. Pitt B, Segal R, Martinez FA, Meurers G, Cowley AJ et al (Elite study investigators) (1997): Randomized trial of losartan versus Captopril in patients over 65 with heart failure (Evaluation of the losartan in the elderly study, ELITE). Lancet 349: 747–752.PubMedCrossRefGoogle Scholar
  37. Pitt B, Poole-Wilson PA, Segal R, Martinez FA et al (2000): Effect of losartan compared with Captopril on mortality in patients with symptomatic heart failure: randomised trial — the Losartan Heart Failure Survival Study ELITE II. Lancet 355: 1582–1587.PubMedCrossRefGoogle Scholar
  38. PROGRESS Collaborative Group (2001): Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet 358: 1033–1041.CrossRefGoogle Scholar
  39. Ruggenenti P, Perna A, Gherardi G, Gaspari F, Benini R, Remuzzi G for the GISEN-Group (1998): Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial. Lancet 352: 1252–1256.PubMedCrossRefGoogle Scholar
  40. Saunders E, Weir MR, Kong BW, Hollifield J, Gray J, Vertes V et al (1990): A comparison of the efficacy and safety of a beta-blocker, a calcium channel blocker, and a converting enzyme inhibitor in hypertensive blacks. Arch Intern Med 150: 1707–1713.PubMedCrossRefGoogle Scholar
  41. Schrader J, Lüders S, Kulschewski A, Berger J et al on behalf of the ACCESS Study Group (2003) The ACCESS Study. Evaluation of acute candesartan cilexetil therapy in stroke survivors stroke 34: 1699–1703.Google Scholar
  42. Svensson P, de Faire U, Sleight P, Yusuf S, Jan Östergren J (2001): Comparative effects of ramipril on ambulatory and office blood pressures. A HOPE substudy Hypertension 38: e28–e32Google Scholar
  43. Teo KK, Yusuf S, Pfeffer M, Torp-Pedersen C, Kober L, Hall A et al and the ACE Inhibitors Collaborative Group (2002): Effects of long-term treatment with angiotensin-converting enzyme inhibitors in the presence or absence of aspirin: a systematic review. Lancet 360: 1037–1043.PubMedCrossRefGoogle Scholar
  44. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators (1993): Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 342: 821–828.Google Scholar
  45. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group (2002). Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 288: 2981–2997.CrossRefGoogle Scholar
  46. The EUCLID Study Group (1997): Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbumi-nuria or microalbuminuria. Lancet 349: 1787–1792.CrossRefGoogle Scholar
  47. The EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators (2003): Efficacy of Perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 362: 782–787CrossRefGoogle Scholar
  48. The GISEN Group (1997): Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 349: 1857–1863.CrossRefGoogle Scholar
  49. The Heart Outcomes Prevention Evaluation (HOPE) Study Investigators (2000a): Effects of an angiotensin-converting-enzyme inhibitor, Ramipril, on cardiovascular events in high-risk patients. N Engl J Med 342: 145–153.CrossRefGoogle Scholar
  50. The Heart Outcomes Prevention Evaluation (HOPE) Study Investigators (2000b): Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 355: 253–259.CrossRefGoogle Scholar
  51. UK Prospective Diabetes Study Group. (1998): Efficacy of atenolol and Captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. Br Med J 317: 713–720.CrossRefGoogle Scholar
  52. White HD (2003): Commentary. Candesartan and heart failure: the allure of CHARM. Lancet 362: 754–755PubMedCrossRefGoogle Scholar
  53. Wing LMH, Reid MC, Ryan P, Beilin LJ et al for the Second Australian National Blood Pressure Study Group (2003): A comparison of outcomes with angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med 348: 583–592.PubMedCrossRefGoogle Scholar
  54. Yusuf S (2002): From the HOPE to the ONTARGET and the TRANSCEND studies: challenges in improving prognosis. Am J Cardiol 89(2A): 18A–25A.PubMedCrossRefGoogle Scholar
  55. Yusuf S, Pfeffer MA, Swedberg K, Granger CB et al (2003): Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 362: 777–781.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2004

Authors and Affiliations

  • Manfred Anlauf
    • 1
  1. 1.Bremerhaven

Personalised recommendations